MM&M

Cingulate signs commercialization agreement with Indegene for ADHD drug

Biopharma company Cingulate announced a joint commercialization agreement with Indegene this week, which pushes forward Cingulate’s lead drug candidate for attention deficit/hyperactivity disorder ...
Yahoo Finance

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

KANSAS CITY, Kan., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing ...
ALZFORUM

Hyperconnectivity in Cingulate Precedes Amyloid. Astrocytes to Blame?

Decades before Alzheimer’s disease symptoms appear, neurons become hyperactive, and the reason could be that astrocytes fail to keep them in check. In a bioRxiv preprint uploaded on April 26, ...
Yahoo Finance

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing ...
Benzinga.com

Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Benzinga.com

What's Going On With Cingulate Shares Recently?

Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...